Host Cell Protein Clinical Safety Risk Assessment—An Updated Industry Review

生物制药 风险评估 鉴定(生物学) 风险分析(工程) 设计质量 产品(数学) 工艺安全 质量(理念) 新产品开发 过程(计算) 良好制造规范 业务 药物开发 计算机科学 医学 药品 工程类 生物技术 运营管理 在制品 药理学 监管事务 几何学 营销 哲学 操作系统 认识论 生物 植物 计算机安全 数学
作者
Lisette Coye,Marisa Jones,Georgeen Gaza‐Bulseco,Carmelata Chitikila,Séverine Clavier,Delphine Fougeron,Christine Grimaldi,Karen Hurkmans,Richard W. Hutchinson,Brenda Kellogg,Xinrong Liu,Nisha Palackal,Mahima Tank,Pascal Valax,Thomas Waerner,Fengqiang Wang,Zhang Ying,Yiwei Zhao,S Sloan,Christina L. Zuch de Zafra
出处
期刊:Biotechnology and Bioengineering [Wiley]
卷期号:122 (11): 3229-3248
标识
DOI:10.1002/bit.70029
摘要

ABSTRACT Host cell proteins (HCP) are process‐related impurities that can co‐purify with therapeutic proteins. Some HCP impurities potentially can have an impact on patient safety (immunogenicity or toxicity), efficacy, and/or product quality. It is important to reduce the levels of HCP impurities with a well‐controlled manufacturing process and to monitor levels with a suitable analytical assay. Biopharmaceutical companies are now routinely using mass spectrometry to identify HCPs which are present in process intermediates and potentially in bulk drug substances and using the data to make decisions to continuously improve their processes and mitigate the potential risk to patients. Some companies perform identification of HCPs starting from the nonclinical stage of development, while others perform HCP identification at later stages or as a part of root cause analysis for identified HCP ELISA‐related issues, process, and product quality or safety concerns. No matter the approach, a comprehensive risk assessment framework for identified HCPs is needed to support decision‐making during development and is expected by regulators to ensure a safe and efficacious drug product. In this paper the BioPhorum Development Group HCP Workstream has brought together a team of industry experts to build upon existing risk assessment frameworks (e.g., de Zafra et al., 2015) and developed recommendations for assessment of clinical safety risks upon identification of individual HCPs, incorporating regulatory considerations and industry experience and using a real‐world case study to illustrate the use of the updated frameworks. Key recommendations include conducting clinical risk assessment alongside product quality risk assessment following individual HCP identification and quantitation; focusing on biological activity and immunogenicity for any HCPs of concern; and communicating and collaborating effectively across functions to enable a comprehensive risk assessment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蓝田完成签到,获得积分10
1秒前
1秒前
我是老大的应助被龙痕采纳,获得10
1秒前
1秒前
2秒前
3秒前
4秒前
ln完成签到 ,获得积分10
4秒前
深情安青的应助被xuan采纳,获得10
6秒前
7秒前
wu发布了新的文献求助10
7秒前
7秒前
8秒前
一颗苹果发布了新的文献求助10
8秒前
Bruce_Wayne发布了新的文献求助10
8秒前
脚踏实地i发布了新的文献求助10
8秒前
8秒前
乐观迎天完成签到,获得积分10
10秒前
10秒前
丰富的安梦完成签到,获得积分10
11秒前
ccc发布了新的文献求助10
11秒前
12秒前
Ggbo完成签到,获得积分10
13秒前
香蕉觅云的应助被小天采纳,获得10
14秒前
14秒前
15秒前
YJY完成签到 ,获得积分10
16秒前
Lily发布了新的文献求助10
16秒前
Nefilibata发布了新的文献求助10
17秒前
JamesPei的应助被lzh采纳,获得10
18秒前
19秒前
123发布了新的文献求助10
20秒前
龙痕完成签到,获得积分10
21秒前
小马甲的应助被慢慢采纳,获得10
22秒前
挽风完成签到 ,获得积分10
22秒前
公爵完成签到,获得积分10
23秒前
23秒前
23秒前
心动动完成签到 ,获得积分10
24秒前
脚踏实地i完成签到,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183414
求助须知:如何正确求助?哪些是违规求助? 9572730
关于积分的说明 21827174
捐赠科研通 7780508
什么是DOI,文献DOI怎么找? 3434008
关于科研通互助平台的介绍 2558183
邀请新用户注册赠送积分活动 2480343